Inactive Instrument

Venn Life Sciences Holdings Stock price London S.E.

Equities

GB00B9275X97

Biotechnology & Medical Research

Sales 2023 * 66.57M 71.88M Sales 2024 * 73.39M 79.25M Capitalization 229M 248M
Net income 2023 * 10M 10.8M Net income 2024 * 10M 10.8M EV / Sales 2023 * 2.8 x
Net cash position 2023 * 43.31M 46.77M Net cash position 2024 * 51.39M 55.49M EV / Sales 2024 * 2.43 x
P/E ratio 2023 *
22.2 x
P/E ratio 2024 *
21.1 x
Employees -
Yield 2023 *
1.38%
Yield 2024 *
0.61%
Free-Float 60.77%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Venn Life Sciences Holdings

Managers TitleAgeSince
Chief Executive Officer 55 21-10-12
Founder 37 11-01-31
Director of Finance/CFO 61 17-06-30
Members of the board TitleAgeSince
Director/Board Member 57 22-06-07
Founder 73 18-11-30
Director/Board Member 63 20-11-23
More insiders
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock hVIVO plc
  4. Stock Venn Life Sciences Holdings - London S.E.